The usefulness of autologous bone marrow transplantation (ABMT) in cancer therapy is limited by uncertainty over the contribution of residual malignant cells in harvested """"""""remission"""""""" marrow to recurrence of the disease. Human marrow progenitor cells will be marked with a retrovirally introduced gene (NeoR) to assess the potential of reinfused marrow to contribute to relapse in patients with acute myelogenous leukemia (AML). If the marked cells do contribute to disease recurrence, a second hypothesis will be tested, namely, that marrow purging can remove the malignant blasts before infusion. Information generated by this study will provide insight into the mechanism(s) of relapse after ABMT and an estimate of the value of pretransplant marrow purging. Since retrovirus-mediated gene transfer marks normal as well as leukemic marrow progenitor cells, the information obtained will also be relevant to the biology of marrow ontogeny in man, making it possible, for example to test the contribution of autologous marrow rescue to long-term hematopoietic reconstitution.
The final aim i s to investigate whether ex vivo treatment of marrow cells with available growth factors will accelerate marrow recovery post-transplantation. If it does, then this approach would simplify the practice and increase the safety of ABMT, particularly if purging - which retards subsequent marrow recovery - proves to be both necessary and effective. If growth factor pretreatment also increases the efficiency and durability of gene transfer, then it will be possible to design protocols for the transfer of therapeutic genes into long-lived marrow progenitor cells. These therapeutic protocols would have wide-ranging application in the treatment of malignant and nonmalignant disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA020180-20
Application #
6101890
Study Section
Project Start
1997-03-15
Project End
1999-02-28
Budget Start
Budget End
Support Year
20
Fiscal Year
1997
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Pieters, Rob; Hunger, Stephen P; Boos, Joachim et al. (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117:238-49
Kaste, Sue C (2011) Imaging pediatric bone sarcomas. Radiol Clin North Am 49:749-65, vi-vii
Kaste, Sue C; Waszilycsak, George L; McCarville, M Beth et al. (2010) Estimation of potential excess cancer incidence in pediatric 201Tl imaging. AJR Am J Roentgenol 194:245-9
Kaste, S C; Thomas, N A; Rai, S N et al. (2009) Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia. Leukemia 23:104-8
Kaste, Sue C; Metzger, Monika L; Minhas, Anum et al. (2009) Pediatric Hodgkin lymphoma survivors at negligible risk for significant bone mineral density deficits. Pediatr Blood Cancer 52:516-21
Martin, Mary Beth; Li, Chin-Shang; Rowland, Christopher C et al. (2008) Correlation of bone age, dental age, and chronological age in survivors of childhood acute lymphoblastic leukaemia. Int J Paediatr Dent 18:217-23
Kaste, Sue C; Ahn, Hyunah; Liu, Tiebin et al. (2008) Bone mineral density deficits in pediatric patients treated for sarcoma. Pediatr Blood Cancer 50:1032-8
Kaste, Sue C (2008) Skeletal toxicities of treatment in children with cancer. Pediatr Blood Cancer 50:469-73;discussion 486
Kaste, Sue C; McCarville, M Beth (2008) Imaging pediatric abdominal tumors. Semin Roentgenol 43:50-9
Marchese, Victoria G; Connolly, Barbara H; Able, Colleen et al. (2008) Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther 88:341-50

Showing the most recent 10 out of 613 publications